

Investigating whether topical application of a non toxic molecule improves epidermal pH and barrier function in atopic dermatitis

Submission date 21/10/2010	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 21/10/2010	Overall study status Completed	☐ Protocol
Last Edited 30/09/2016	Condition category Skin and Connective Tissue Diseases	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Neil Gibbs

Contact details

Dermatological Sciences
Stopford Building
Oxford Road
Manchester
United Kingdom
M13 9PT

-

neil.gibbs@manchester.ac.uk

Additional identifiers

Protocol serial number

7064

Study information

Scientific Title

Investigating whether topical application of a non toxic molecule improves epidermal pH and barrier function in atopic dermatitis

Study objectives

It is understood that the skin of people with atopic dermatitis (AD) does not act as an efficient barrier against chemicals and microbes that can enter the skin. One of the chemicals in the skin that may be important in barrier function is called Filaggrin. This study examines whether application of a naturally-occurring molecule onto the skin of people with AD may improve the barrier function of their skin.

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC, ref: 08/H1009/51

Primary study design

Interventional

Study design

Single-centre randomised interventional trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Skin; Subtopic: Skin (all Subtopics); Disease: Dermatology

Interventions

1. Intervention: Gel containing a naturally-occurring chemical onto the skin of one their forearms every day for 6 weeks
2. Control: On the other forearm they will be asked to apply the same cream/gel that doesn't contain any of the naturally-occurring molecule

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Filaggrin

Primary outcome(s)

Each week volunteers will be asked to complete a short questionnaire (POEM)

Key secondary outcome(s)

1. General skin condition using a well established scoring system for AD (SCORAD)
2. Skin barrier function transepidermal water loss (TEWL), measured at monthly intervals

Completion date

01/01/2011

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/09/2008

Date of final enrolment

01/01/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

The University of Manchester

Manchester

United Kingdom

M13 9PT

Sponsor information

Organisation

Biotechnology and Biological Science Research Council (BBSRC) (UK)

ROR

<https://ror.org/00cwqg982>

Funder(s)

Funder type

Research council

Funder Name

Biotechnology and Biological Sciences Research Council

Alternative Name(s)

UKRI - Biotechnology And Biological Sciences Research Council, Agricultural and Food Research Council, Biotechnology & Biological Sciences Research Council, BBSRC, BBSRC UK, AFRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary